Simultaneous and Rapid Determination of Six Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Using HPLC-MS/MS

Table 5

Inter- and intra-accuracy and precision of six analytes (n = 5).

Analytes	Nominal concentration (ng/ml)	Interday			Intraday
		Measured concentration (mean ± SD)	Accuracy (RE %)	Precision (RSD %)	Measured concentration (mean ± SD)	Accuracy (RE %)	Precision (RSD %)
Gefitinib	20	17.70 ± 0.66	−11.5	3.75	17.32 ± 0.26	−13.4	1.51
	100	87.81 ± 1.81	−12.19	2.06	87.77 ± 2.22	−12.23	2.53
	500	552.89 ± 15.82	10.59	2.86	565.21 ± 9.26	13.04	1.63
Icotinib	100	91.09 ± 0.93	−8.91	1.02	91.56 ± 0.49	−8.44	0.53
	500	439.77 ± 12.18	−12.05	2.77	426.70 ± 1.82	−14.66	0.42
	2000	1919.82 ± 39.30	−0.40	2.04	1966.42 ± 27.49	−1.68	1.39
Erlotinib	100	87.59 ± 1.14	−12.41	1.31	88.94 ± 0.82	−11.06	0.93
	500	441.47 ± 6.58	−11.71	1.50	450.70 ± 1.51	−9.86	0.33
	2000	1887.25 ± 94.36	−5.64	2.19	1933.51 ± 37.33	−3.25	1.93
Crizotinib	20	18.17 ± 0.62	−9.15	3.42	18.55 ± 0.92	−7.25	4.97
	100	91.67 ± 3.11	−8.33	3.39	88.67 ± 1.71	−11.33	1.92
	500	538.54 ± 12.68	7.71	2.35	538.57 ± 4.57	7.71	0.85
Osimertinib	20	18.72 ± 0.92	−6.40	4.92	18.52 ± 0.46	−7.40	2.53
	100	85.36 ± 2.96	−14.64	3.47	85.24 ± 4.95	−14.76	5.81
	500	556.91 ± 11.80	11.38	2.12	561.76 ± 15.24	12.35	2.71
Afatinib	10	9.92 ± 0.53	−0.80	5.41	9.76 ± 0.19	−2.40	1.94
	50	53.78 ± 2.28	7.56	4.24	51.54 ± 1.74	3.08	3.37
	200	217.83 ± 4.73	8.92	2.17	220.65 ± 4.71	10.33	2.13